FORM 2
THE PATENTS ACT 1970
(39 of 1970)
&
The Patent Rules 2005
COMPLETE SPECIFICATION
(see sections 10 & rule 1.3)
1635/MUM/2005 dt 29/12/2005
1. TITLE OF THE INVENTION
"POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND
THEREOF" PROCESSES
2. APPLICANT (S)
NAME NATIONALITY ADDRESS
USV LIMITED INDIAN B.S.D. Marg , Govandi, Mumbai-
400088, INDIA
3. PREAMBLE TO THE DESCRIPTION
COMPLETE SPECIFICATION
The following specification particularly describes the invention and the
it is to be performed. manner in which


POLYMORPHIC FORMS OF DOLASETRON MESYLATE AND PROCESSES
THEREOF
This specification claims priority from 1635/MUM/2005 dt 29/12/2005 and
1610/MUM/2005 dt 23/12/2005
TECHNICAL FIELD
The present disclosure relates to novel crystalline polymorphs of Dolasetron
mesylate having formula (1) and industrial processes for producing the same. Further, it
discloses processes for producing Form I of Dolasetron mesylate. Furthermore, the present
disclosure teaches novel amorphous form and industrial processes for producing
amorphous form.

BACKGROUND AND PRIOR ART
Dolasetron mesylate is an antinauseant and antiemetic agent. It is a selective
serotonin 5-HTa receptor antagonist and is indicated for the prevention of nausea and
vomiting associated with emetogenic cancer chemotherapy.
Synthesis of Dolasetron mesylate is not very widely reported in literature.
EP0266730/US4906755 describes process for the preparation endo-hexahydro-8-(3-
indolylcarbonyloxy)-2,6-methano-2H-quinolizh-3(4H)-one methanesulfonate or
Dolasetron mesylate (1) by the condensation of diethyl malonate with cis-l,4-dichloro-2-
butene (2) in presence of lithium hydride in dimethylformamide to give diethyl-3-
cyc1opentene-],l-dicarboxylate (3), which on hydrolysis and decarboxylation gave 3-
cyclopentene-1-carboxylic acid (4). The compound (4) was further treated with thionyl
chloride and pyridine in ethanol to obtain ethyl 3-cyclopentene-l-carboxylate (5).
Compound (5) was oxidized to 4-ethoxycarbonyl-l, 2-cyclopentanediol (6) by using N-
methylmorpholine N-oxide in the presence of osmium tetroxide catalyst. The diol (6) was
cleaved to the β-ethoxycarbonylglutaraldehyde (7) using sodium periodate and used
directly in the next reaction. Robinson-Schopf cyclisation of the compound (7) with
2

potassium hydrogen phthalate, acetonedicarboxylic acid and glycine ethyl ester
hydrochloride resulted in the pseudopelletierine derivative i.e. 7-ethoxycarbonyl-9-
(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1] nonan-3-one (8). The ketone group of
compound (8) was reduced with sodiumborohydride in ethanol to give 7-ethoxycarbonyl-
9-(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1] nonan-3-ol (9). The reduced alcohol (9)
was treated with dihydropyran to protect the hydroxyl group as a tetrahydropyranyl ether
(10). Dieckmann cyclisation of the compound (10) using strong base (potassium t-
butoxide) followed by aqueous acid hydrolysis and decarboxylation gave the desired
alcohol. The resulting alcohols can exist in two conformations - axial and equatorial. The
main product obtained by above procedure was the axial alcohol or endo-hexahydro-8-
hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one (11) and it can be separated from the
equatorial isomer by crystallization of the camphorsulfonate or tetrafluoroborate salt. The
tetrafluoroborate salt of endo-hexahydro-8-hydroxy-2,6-rnethano-2H-quinolizin-3-(4H)-
one (11) was further reacted with 3-indolecarboxylic acid chloride in presence of silver
tetrafluoroborate in anhydrous nitroethane at -78°C to endo-hexahydro-8-(3-
indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one or Dolasetron base, which
was further converted into Dolasetron mesylate monohydrate (Scheme I) with a yield of
66%. No further purification is described.
The above process uses column chromatography for purification of compounds (9)
and (10), which is expensive, time consuming and impractical on an industrial scale. The
above patent does not disclose the yield and purity of Dolasetron mesylate obtained and so
also for the intermediates. In addition, Osmium tetroxide used for preparation of
compound (6) is toxic, has a corrosive action on eyes and hence difficult to use at
industrial scale. Also, this process uses high volume of water during preparation of the
compound (8); preparation of compound (11) from compound (10) is tedious, because the
workup involves several extractions with ethyl acetate and preparation of compound (1) in
presence of silver terrafluoroborate involves the use of expensive silver compound.
3


Another method described in EP0339669 provides a process for the preparation of
endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate or Dolasetron mesylate (1) by the condensation of dimethyl malonate
with cis-l,4-dichloro-2-butene (2) in presence of lithium hydride in dimethyl formamide
to give dimethyl-3-cyclopentene-l,l-dicarboxylate (12), which was decarboxymethylated
to obtain methyl-3-cyclopentene-l-carboxylate (13). This compound (13) was treated with
m-chloroperbenzoic acid in dichloromethane to obtain l-methoxycarbonyl-3-
cyclopenteneoxide (14). The compound (13) on ozonolysis gave β-
4

methoxycarbonylglutaraldehyde (15) or the epoxide (14) was reacted with periodic acid to
obtain the (3-methoxycarbonylglutaraIdehyde (15), which was used directly in the next
reaction. Robinson-Schopf cyclisation of the compound (15) with potassium hydrogen
phthalate, acetonedicarboxylic acid and glycine ethyl ester hydrochloride gave the
pseudopelletierine derivative i.e. 7-methoxycarbonyl-9-(methoxycarbonyImethyl)-9-
azabicyclo [3-3.1] nonan-3-one (16). The ketone group of compound (16) was reduced
with sodiumborohydride in methanol to give 7-methoxycarbonyl-9-
(methoxycarbonylmethyI)-9-azabicyclo-[3.3.1]nonan-3-oI (17). The reduced alcohol (17)
was treated with dihydropyran to protect the hydroxyl group as a tetrahydropyranyl ether
(18a) or treated with methylal to protect the hydroxyl group to obtain 3-methoxymethoxy.
7-methoxycarbonyl-9-(methoxycarbonylmethyl)-9-azabicyclo[3.3.1 ]nonan-3-ol (18b).
Dieckmann cyclisation of the compound (18) using strong base (potassium t-
butoxide) followed by aqueous acid hydrolysis and decarboxylation gave the endo-
hexahydro-8-hydroxy-2, 6-methano-2H-quinolizin-3-(4H)-one (11). The alcohol (11) was
further reacted with 3-indolecarboxylic acid in presence of trifluoroacetic anhydride in
dichloromethane to endo-hexahydro-8-(3-indolylcarbonyloxy)-2, 6-methano-2H-
quinolizin-3(4H)-one or Dolasetron base, which was then converted into Dolasetron
mesylate (1) (Scheme II) by treating with methanesulphonicacid in acetone. Further,
crude Dolasetron mesylate (1) was dissolved in aqueous isopropanol and regenerated by
adding ether to obtain Dolasetron mesylate (1) with a yield of 85.90 %.
Disadvantages of this process are:
(i) use of high volume of water for preparation of compound (16) and
(ii) preparation of compound (11) from compound (18) which is tedious because at
the time of workup, ethyl acetate extractions take up longer period (20 hr);
The process is not only time consuming but also expensive on an industrial scale.
The patent does not disclose purity of Dolasetron obtained nor for any of the
intermediates.
5


The process as described in EP 0266730 involves treatment of endo-hexahydro-8-
(3-indolyIcarbonyIoxy)-2, 6-methano-2H-quinolizin-3(4H)-one with a solution of methane
sulfonic acid in ethanol to provide Dolasetron mesylate monohydrate. EP 0339669
describes crystallization of crude Dolasetron mesylate by dissolution in aqueous
isopropanol and regeneration by adding ether. The polymorphic form obtained by the
processes described in US 4906755/EP 0266730 and EP 0339669 is designated herein as
Dolasetron mesylate Form 1. XRPD of Dolasetron mesylate Form I is disclosed in Figure
1.
6

The ability of the compound to exhibit more than one orientation or conformation
of molecule within the crystal lattice is called polymorphism. Many organic compounds
including active pharmaceutical ingredients (API's) exhibit polymorphism.
Drug substance existing in various polymorphic forms differs from each other in
terms of stability, solubility, compressibility, flowability and spectroscopic properties,
thus affecting dissolution, bioavailability and handling characteristics of the substance.
Rate of dissolution of an API's in patient's stomach fluid can have therapeutic
consequences since it imposes an upper limit on the rate at which an orally administrated
API can reach the patient bloodstream. Flowability affects the ease with which the
material is handled while processing a pharmaceutical product.
Investigation of crystal polymorphism is an essential step in pharmaceutical
research due to the influence of solid-state properties on dosage form.
As the polymorphs are known to possess different spectroscopic properties,
technique such as X-Ray powder diffraction (XRPD), Fourier transformer Infrared (FT-
IR) spectroscopy, Solid State 13C-NMR, and thermal method of analysis are keys to
identify and characterize the new polymorphs or existing polymorphs.
The discovery of new polymorphs with same or better pharmaceutical equivalence
and bioequivalence as that of the known polymorphs provides an opportunity to improve
the performance characteristic of the pharmaceutical product.
Polymorphs of Dolasetron mesylate are not widely reported. CN 1629161
discloses a crystalline polymorph of Dolasetron mesylate monohydrate.
In our endeavour to develop a process for the purification of Dolasetron mesylate. we have
surprisingly discovered novel polymorphic forms Dolasetron mesylate.
OBJECTS OF THE PRESENT INVENTION
It is an object of the present disclosure to provide novel polymorphic forms of
Dolasetron mesylate and industrial processes for producing them.
Another object is to provide a process for preparation of Dolasetron mesylate
polymorphic Form I.
It is also an object of to provide novel amorphous form of Dolasetron mesylate and
industrial processes for producing it.
SUMMARY OF THE INVENTION
7

Accordingly, the present disclosure provides a process for the preparation of a
crystalline polymorphic Form I of endo-hexahydro-8-(3-indolylcarbonyloxy)-2, 6-
methano-2H-quinolizin-3 (4H)-one methanesulfonate (Dolasetron mesylate).
In one aspect, the present invention provides a crystalline polymorphic Form II of
endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides a process for producing
polymorphic Form II of Dolasetron mesylate.
In one aspect, the present invention provides a crystalline polymorphic Form III of
endo-hexahydro-8-(3-indolylcarbonyloxy)-2;6-methano-2H-quino]izin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides a process for producing
polymorphic Form III of Dolasetron mesylate.
In one aspect, the present invention provides a crystalline polymorphic Form IV of
endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In a further aspect, the present invention relates to a process for producing
polymorphic Form IV of Dolasetron mesylate.
In one aspect, the present invention provides a crystalline polymorphic Form V of
endo-hexahydro-8-{3 -indoly Icarbony loxy)-2,6 -methano-2 H-quinolizin-3 (4H) -on e
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides a process for producing
polymorphic Form V of Dolasetron mesylate.
In yet another aspect, the present invention provides a crystalline polymorphic
Form VI of endo-hexahydro-8-(3-indoIyIcarbonyloxy)-2,6-methano-2H-quinolizin-
3(4H)-one methanesulfonate, Dolasetron mesylate,
In a further aspect, the present invention provides a process for producing
polymorphic Form VI of Dolasetron mesylate.
8

In one aspect, the present invention provides a crystalline polymorphic Form VII
of endo-hexahydro-8-(3-indoIyIcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides a process for producing
polymorphic Form VII of Dolasetron mesylate.
In yet another aspect, the present invention provides a crystalline polymorphic
Form VIII of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-
3(4H)-one methanesulfonate, Dolasetron mesylate.
In a further aspect, the present invention provides a process for producing
polymorphic Form VIII of Dolasetron mesylate.
In one aspect, the present invention provides a crystalline polymorphic Form IX of
endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides a process for producing
polymorphic Form IX of Dolasetron mesylate.
In one aspect, the present invention provides an amorphous form of endo-
hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one
methanesulfonate, Dolasetron mesylate.
In another aspect, the present invention provides processes for preparation of
amorphous form of Dolasetron mesylate.
BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
Figure 1 shows XRPD pattern of Dolasetron mesylate Form I
Figure 2 shows XRPD pattern of Dolasetron mesylate Form II
Figure 3 shows XRPD pattern of Dolasetron mesylate Form III
Figure 4 shows XRPD pattern of Dolasetron mesylate Form IV
Figure 5 shows XRPD pattern of Dolasetron mesylate Form V
Figure 6 shows XRPD pattern of Dolasetron mesylate Form VI
Figure 7 shows XRPD pattern of Dolasetron mesylate Form VII
Figure 8 shows XRPD pattern of Dolasetron mesylate Form VIII
Figure 9 shows XRPD pattern of Dolasetron mesylate Form IX
Figure 10 shows XRPD pattern of amorphous form of Dolasetron mesylate
9

DETAILED DESCRIPTION OF THE INVENTION
The present disclosure relates to a process for preparation of Dolasetron mesylate
or endo-hexahydro-8-(3-indolylcarbonyloxy)-2, 6-methano-2H-quinolizin-3 (4H)-one
methanesulfonate of the formula (1) in high yield and high purity comprising:

a. reacting compound (4)

with thionyl chloride in alcohol or alcoholic hydrochloric acid or anhydrous HC1 gas to
form compound having the structural formula (V);

Formula (V)
b. treating the compound having the structural formula (V) with m-chloroperbenzoic acid
in dichloromethane to give an epoxide having the structural formula (XIX),
I
Formula (XIX)
c. treating the epoxide having the structural formula (XIX) with periodic acid to give
compound having the structural formula (VII);

10


d. cyclising the compound having the structural formula (VII) with potassium hydrogen
phthalate, acetonedicarboxylic acid and glycine ester hydrochloride by Robinson-
Schopf cyclisation to obtain pseudopelletierine derivative having the structural
formula (VIII);

Formula (VIII)
e. reducing the compound having the structural formula (VIII) with sodiumborohydride
in alcohol followed by treatment with an organic acid to obtain compound having the
structural formula (IX);
i

Formula (IX)
f. protecting the compound having the structural formula (IX) as a silyl derivative
having the structural formula (XX) by treating it with a silyl halide in an organic
solvent (wherein Z = silyl group);

Formula (XX)

11

g. treating the compound having the structural formula (XX) with a strong base to form
compound having the structural formula (XXI);

Formula (XXI)
h. treating the compound having the structural formula (XXI) with acid in water or an
organic solvent followed by decarboxylation to yield compound (11);

Compound (11)
i. reacting the compound (11) with indole-3-carboxylic acid in presence of
trifluoroacetic acid anhydride to yield Dolasetron base; and
j. converting the Dolasetron base into its mesylate; and recrystallizing from a mixture
of solvents to obtain highly pure compound (1);
wherein, R = Et, Me, or OCH2Ph, R, = Et, Me, or OCH2Ph and Z is selected from
trimethyl silyl, isopropyl dimethyl silyl, t-butyldimethyl silyl, t-butyldiphenyl silyl,
tribenzyl silyl, and triisopropyl silyl.
In accordance to above, Scheme III as given below depicts a process for the
preparation of 3-cyclopentene-l-carboxylic acid ester (5) is disclosed, said process
comprising: reacting 3-cyclopentene-l-carboxylic acid (4) with anhydrous HC1 gas or
concentrated hydrochloric acid or thionyl chloride in an alcohol, wherein the alcohol is
either methanol or ethanol; treating the compound (5) with m-chloroperbenzoic acid in a
solvent selected from dichloromethane and ethyl acetate to obtain the corresponding
epoxide (19); reacting the compound (19) with periodic acid under nitrogen atmosphere to
obtain compound (7); treating the compound (7) with potassium hydrogen phthalate,
acetonedicarboxylic acid and glycine ester hydrochloride in water to obtain
pseudopelletierine derivative (8); reducing the compound (8) with sodiumborohydride in
12

an alcohol and further treating with an organic acid to obtain compound (9), wherein the
organic acid is selected from formic acid, methane sulphonic acid and acetic acid; treating
the compound (9) with silyl halide in presence of imidazole in an organic solvent to obtain
compound (20), wherein the organic solvent is selected from ketones, esters and ethers,
preferably from acetone, tetrahydrofuran, 1, 4-dioxane, dichloromethane, chloroform, N,
N-dimethyl formamide, ethyl acetate and acetonitrile.
13


(Dolasetron base)
A major advantage of the use of silyl protecting group is that it yields greater than
95 % of compound (20) as compared to, use of dihydropyran (75%) or methylal (84%).
The compound (20) is treated with a strong base in toluene and further treated
with an organic acid in an organic solvent to form compound (21). The organic solvent is
selected from halogenated solvents, ethers and esters. The organic solvent is preferably
selected from methylene chloride, chloroform, ethyl acetate, isopropyl acetate, diethyl

14
14


ether, diisopropyl ether or mixtures thereof. The organic acid is selected from formic acid
and acetic acid.
The compound (21) is heated with hydrochloric acid in water to give compound
(11). Hydrochloric acid and water are used in the ratio of 1:2 volumes. The ratio of
compound (21) to water in the reaction is about 1: 8 to 1:10. The reaction mixture is
concentrated and the residue obtained is treated with an organic solvent and filtered. The
filtrate is concentrated to obtain compound (11). The organic solvent is selected from
alcohols and halogenated solvent preferably methanol, ethanol, isopropanol, n-butanol,
dichloromethane, chloroform or mixture thereof. The reaction mixture is extracted with an
organic solvent selected from ethyl acetate, isopropanol or n-butanol. Alternately the
reaction mixture is saturated with an inorganic salt and extracted with an organic solvent
selected from ethyl acetate or n-butanol or isopropanol.
The compound (11) is reacted with indole-3-carboxylic acid in presence of
trifluoroacetic acid anhydride in dichloromethane to give Dolasetron base. The ratio of
indole-3-carboxylic acid and trifluoro acetic anhydride used is in the range of 1:1.1 to 1:2.
Dolasetron base thus obtained is isolated by conventional method, Dolasetron base is
solubilized in acetone and converted into its mesylate salt using methane sulphonic acid.
The resultant mesylate salt is dissolved in water and extracted with a halogenated solvent
or ester to remove traces of impurity. The halogenated solvent is selected from
dichloromethane and chloroform, and the ester is selected from methyl acetate, ethyl
acetate and isopropyl acetate. The aqueous layer is basified with a base to obtain
Dolasetron base. The base is selected from sodium carbonate, potassium carbonate,
sodium bicarbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide or
mixtures thereof. Dolasetron base thus obtained is treated with methane sulphonic acid in
a mixture of acetone and water to provide Dolasetron Mesylate.
Polymorphic forms of Dolasetron mesylate
One more embodiment of the invention provides novel crystalline polymorphic
forms, viz: Form II, Form III, Form IV, Form V, Form VI, Form VII, Form VIII and Form
IX.
Another embodiment of the invention provides a process for manufacturing these
crystalline polymorphic forms. The invention also discloses novel amorphous form of
Dolasetron mesylate.
15

The polymorphic Form I of Dolasetron mesylate is obtained by crystallization. The
process involves, dissolving Dolasetron mesylate in a solvent selected from aliphatic
alcohols, aliphatic ketones, aliphatic esters, aliphatic nitriles or mixtures thereof at a
temperature in the range of 30°C-80°C to yield a clear solution. The clear solution is
cooled at a temperature in the range of 00C-30°C, preferably in the range of 25°C-30°C to
obtain a solid. Dolasetron mesylate form I is obtained by filtering and drying the solid at a
temperature in the range of 30°C-90°C, preferably in the range of 60°C-70°C. The
aliphatic alcohol selected is isopropanol; the aliphatic ester is selected from methyl
acetate, ethyl acetate and butyl acetate; aliphatic ketone is selected from acetone, 2-
butanone, diethylketone, and the like; and aliphatic nitrile is acetonitrile.
Dolasetron mesylate Form I is also obtained by solvent and anti-solvent process.
The said process comprises: dissolving Dolasetron mesylate in a solubilizing solvent,
adding an anti-solvent, stirring the suspension with or without cooling, isolating and
drying the product at 50°C-70°C. The solubilizing solvents selected for dissolution are
polar aprotic solvents. The polar aprotic solvent is selected from N, N-dimethyl
formamide, dimethyl sulfoxide and N, N-dimethyl acetamide. The anti-solvent is selected
from cyclic ethers, aromatic hydrocarbons and alcohols. The cyclic ether selected is
tetrahydrofuran. The aromatic hydrocarbon is toluene and the alcohol is isopropanol.
The XRPD of Dolasetron mesylate Form I exhibit following peaks:

Position [°2θ] Rel. Int. [%]
7.4587 6.15
9.9618 22.96
10.5229 11.60
11.8311 13.91
12.2113 46.32
12.8014 16.93
13.0334 69.03
13.9997 5.05
14.7702 4.51
15.2057 48.73
15.4577 22.29
16.3397 6.45
16.7613 7.33
17.1873 39.45
18.0049 21.19
18.2978 10.25
19.0431 73.21
19.3804 25.15
16

19.8238 84.20
20.1208 70.13
20.4718 6.81
21.1534 32.28
22.1965 41.40
22.5131 100.00
22.9364 21.29
23.1046 18.63
23.5992 21.37
24.3924 29.65
24.7468 24.62
25.0691 12.40
25.6221 16.23
26.0495 18.98
26.6353 30.98
27.2251 16.77
28.0475 24.76
28.8492 15.82
29.9349 24.37
30.2157 65.62
30.5167 12.70
31.0803 9.84
31.6533 17.87
32.8171 11.68
33.3453 11.07
33.8520 15.00
34.5881 6.22
35.5587 9.61
36.6675 15.29
37.9088 6.97
38.7741 7.86
40.5258 8.59
42.5248 5.86
42.9394 10.15
43.5589 8.97
44.8652 3.63
46.3824 6.20
49.1697 6.31
The polymorphic Form II is obtained by crystallizing Dolasetron mesylate from
methanol. The polymorphic Form II is obtained by dissolving Dolasetron mesylate in
methanol at a temperature in the range of 30-80°C, preferably in the range of 60-70°C,
cooling the solution at a temperature in the range of -5°C to 25°C, preferably in the range
of 2 to 7°C, isolating and drying the product at a temperature in the range of in the range
of 40-90°C, preferably in the range of in the range of 60-70°C. The XRPD of Dolasetron
17

mesylate Form II is given in Figure 2. The XRPD of Dolasetron mesylate Form II exhibits
following peaks:

Position [°2θ] Rel. Int. [%]
8.5677 6.09
10.0288 15.17
11.2894 4.56
12.1224 11.85
14,3549 6.44
15.3566 37.98
16.1189 100.00
17.4727 33.33
17.9848 13.61
18.2788 17.61
18.6717 7.36
19.0521 5.06
19.4583 24.09
19.9142 58.36
20.3327 62.55
20.7258 84.65
21.4927 21.14
22.8359 11.20
23.1023 10.08
24.4864 23.47
25.8654 10.96
27.1036 10.58
27.5344 32.07
27.8212 8.51
28.2995 54.08
30.0154 6.14
30.3489 6.50
30.8158 15.55
31.1764 9.57
32J019 8.14
32.4852 8.13
32.7724 7.66
33.6263 4.20
34.9029 2.52
35.7768 7.29
36.9416 6.79
37.2354 6.99
39.4576 3.12
39.9761 7.25
42.1000 1.20
45.1580 1.23
47.4886 1.74
49.5076 4.99
18

The polymorphic Form III is obtained by crystallizing Dolasetron mesylate from
ethanol. The polymorphic Form III is obtained by dissolving Dolasetron mesylate in
ethanol at a temperature in the range of 30-80°C, preferably in the range of 75-80°C,
cooling the solution at a temperature in the range of-5°C to 25°C, preferably in the range
of 2 to 7°C, isolating and drying the product at a temperature in the range of in the range
of 40-90°C, preferably in the range of 60-70°C.
Also, the polymorphic Form III is obtained by using solvent and anti-solvent
combination process. The said process comprises: dissolving Dolasetron mesylate in a
solubilizing solvent at a temperature in the range of 30-80°C, preferably in the range of
60-80°C, adding an anti-solvent at a temperature in the range of 30-55°C, preferably in the
range of 40-50°C, isolating and drying the product at a temperature in the range of 40-
90°C, preferably in the range of 60-70°C. The solubilizing solvents are selected from
lower aliphatic alcohols. The lower alcohol is selected from methanol, ethanol, n-propanol
and isopropanol, preferably ethanol. The anti-solvent is selected from aliphatic
hydrocarbons n-pentane, n-hexane and n-heptane, preferably n-hexane. The XRPD of
Dolasetron mesylate Form III is given in Figure 3. The XRPD of Dolasetron mesylate
Form III exhibits following peaks:

Position [°2θ] Rel. Int. [%]
6.9327 2.87
9.8793 4.08
11.7303 2.68
12.6509 100.00
13.7701 15.97
16.6416 21.33
17.5613 18.64
18.1133 66.76
19.4364 37.96
19.6530 70.74
20.5969 43.14
21.2122 42.37
22.1215 27.17
22.3203 29.08
22.9997 14.64
23.2369 29.45
25.3464 22.52
25.7644 7.93
26.7943 11.14
27.9040 44.38
28.2908 11.30
29.5991 19.08
31.3094 10.72
19

31.5560 10.97
32.6826 7.96
34.1101 5.85
34.5722 6.62
34.9579 7.12
36.3803 5.26
37.6469 3.01
39.6600 3.13
40.8489 2.61
41.6942 4.21
44.2459 1.74
45.3305 1.76
Polymorphic Form IV is obtained by crystallizing Dolasetron mesylate from n-
propanol. The polymorphic Form IV is obtained by dissolving Dolasetron mesylate in n-
propanol at a temperature in the range of 30-100°C, preferably in the range of 90-100°C,
cooling the solution at a temperature in the range of-5°C to 25°C, preferably in the range
of 2 to 7°C, isolating and drying the product at a temperature in the range of in the range
of 40-90°C, preferably in the range of in the range of 60-70°C.
The XRPD of Dolasetron mesylate Form IV is given in Figure 4. The XRPD of
Dolasetron mesylate Form IV exhibits following peaks:

Position
[°2θ] Rel. Int. [%]
8.9231 13.20
9.8783 4.58
11.0009 9.65
12.1275 12.74
12.5348 16.42
12.7100 4.78
12.9295 13.19
13.5324 7.67
14.0712 68.91
14.4080 17.98
14.8069 33.77
15.1068 19.18
15.4202 20.16
16.6676 24.07
17.0883 13.11
17.3884 18.93
17.8087 20.51
18.1597 14.53
18.9666 19.40
19.2953 26.33

20

19.9217 100.00
20.3947 24.69
20.8115 42.34
21.6045 15.47
22.0471 73.52
22.4082 27.53
23.0366 20.15
23.5718 9.97
24.3224 22.76
25.0364 18.40
26.3036 14.18
27.4731 33.17
28.2271 10.21
29.2801 22.56
30.1751 24.53
32.7579 11.03
33.6510 11.10
36.5575 6.71
40.5518 2.52
Polymorphic Form V is obtained by crystallizing Dolasetron mesylate from
chlorinated hydrocarbons. The polymorphic Form V is obtained by dissolving Dolasetron
mesylate in a solubilizing solvent at a temperature in the range of 30-80°C, cooling the
solution at a temperature in the range of-5°C to 30°C, preferably in the range of 25-30°C,
isolating and drying the product at a temperature in the range of in the range of 40-90°C,
preferably in the range of in the range of 60-70°C. The solubilizing solvent is chlorinated
hydrocarbon and is selected from methylene dichloride or chloroform. The XRPD of
Dolasetron mesylate Form V is given in Figure 5. The XRPD of Dolasetron mesylate
Form V exhibits following peaks:

Position [°2θ] Rel. Int. [%]
7.0234 2.39
9.4499 10.44
10.0014 1.75
11.2346 6.13
12.3990 41.17
13.0876 5.00
13.5899 16.75
14.2116 34.51
14.9901 23.78
16.4007 16.49
16.5997 10.27
17.2415 2.93
21

18.7313 61.04
19.3572 11.87
19.9122 7.47
20.3109 37.22
20.7126 63.91
21.2339 42.10
22.2956 100.00
23.8661 22.10
24.2519 26.86
24.8389 22.90
25.7209 4.60
26.7060 5.14
27.1085 15.85
27.8334 9.48
28.2062 21.05
28.8706 29.90
29.6637 32.04
30.2901 8.68
31.0608 17.14
31.3191 15.03
33.4700 8.81
34.8387 8.04
35.4257 5.99
36.2944 3.36
39.3031 3.61
40.2044 1.49
40.7189 2.00
41.9681 2.42
42.9023 5.63
44.2007 3.48
45.7069 4.46
48.3668 2.41
Polymorphic Form VI is obtained from Dolasetron mesylate by solvent and anti-
solvent combination process. The said process comprises of dissolving Dolasetron
mesylate in a solubilizing solvent like a polar aprotic solvent at a temperature in the range
of 20-35°C, preferably in the range of 25-30°C, adding an anti-solvent at a temperature in
the range of 20-45°C, preferably in the range of 25-30°C, isolating and drying the product
at a temperature in the range of 40-90°C, preferably in the range of 60-70°C. The polar
aprotic solvent selected for dissolving Dolasetron mesylate is dimethyl formamide or
dimethyl sulfoxide. The anti-solvent is selected from cyclic ethers such as 1, 4-dioxane.
The XRPD of Dolasetron mesylate Form VI is given in Figure 6. The XRPD of
Dolasetron mesylate Form VI exhibits following peaks:
22

Position [°2θ] Rel. Int. [%]
7.4433 5.63
9.5049 20.13
9.9496 13.90
10.5039 6.65
11.8166 5.42
12.1944 18.96
12.6288 29.00
13.0077 30.68
13.3801 4.62
13.7613 2.83
14.7330 2.72
15.1734 34.41
15.4668 12.92
16.6316 24.00
17.1629 26.82
17.8499 53.38
19.0352 100.00
19.3432 89.80
19.8030 46.30
20.0712 36.98
20.4909 65.99
20.9356 8.65
21.3421 21.25
21.8514 7.35
22.1111 35.66
22.5010 57.85
22.7995 32.62
23.0903 11.37
23.6251 7.97
24.3860 15.83
24.7255 19,47
25.0343 14.83
25.6040 8.62
26.0387 10.14
26.6211 15.13
27.2259 59.06
28.0530 14.52
29.1029 16.69
29.9326 6.76
30.2376 29.39
31.0858 9.70
31.4142 12.45
31.6868 9.26
32.3416 4.26
32.8342 4.78
33.3082 7.59
33.8019 7.03
35.3064 11.79
23

36.6186 5.25
37.6928 2.32
38.5491 2.80
40.8503 3.65
42.9479 2.85
43.5321 4.78
45.8347 5.25
47.0633 3.28
49.2055 2.24
The polymorphic Form VII is obtained from Dolasetron mesylate by solvent and
anti-solvetit combination process. The said process comprises: dissolving Dolasetron
mesylate in a polar aprotic solvent at an ambient temperature in the range of 20-35°C,
preferably in the range of 25-30°C, adding an anti-solvent at a temperature in the range of
20-45°C, preferably in the range of 25-30°C, isolating and drying the product at a
temperatufe in the range of 30-90°C, preferably in the range of 60-70°C. The polar aprotic
solvent is selected as dissolution solvents. The polar aprotic solvent is N, N-dimethyl
acetamide. The anti-solvent is selected from cyclic ethers such as 1, 4-dioxane. The XRPD
of Dolasetron mesylate Form VII is given in Figure 7. The XRPD of Dolasetron mesylate
Form VII exhibits following peaks:

Position [°2θ] Rel. Int. [%]
9.4384 20.32
11.6064 2.06
12.5519 72.26
13.3180 3.73
13.7754 7.33
16.5925 43.77
17.2066 32.10
17.7820 78.62
18.9901 80.48
19.2914 100.00
20.5000 95.46
20.9102 10.74
21.2835 35.90
21.7867 11.90
22.0779 36.86
22.7162 53.61
24.6939 8.55
25.0331 15.90
25.5487 10.34
26.2507 9.33
24

27.1538 57.00
27.7132 4.84
28.2070 7.44
29.0636 18.19
30.9147 10.15
31.3735 14.62
31.7627 9.07
32.3232 4.10
32.9013 5.62
34.0401 7.29
35.2654 13.30
39.1189 3.42
40.7887 3.73
47.0409 3.23
The polymorphic Form VIII is obtained by suspending Dolasetron mesylate in
aliphatic ketones such as ethyl methyl ketone, heating at a temperature in the range of 30-
85°C for one hour, preferably in the range of 75-80°C, stirring the solution with cooling at
a temperature in the range of-5 to 30°C, preferably in the range of 25-30°C, isolating and
drying the product at a temperature in the range of in the range of 40-90°C, preferably in
the range of in the range of 65-70°C. The XRPD of Dolasetron mesylate Form VIII is
given in Figure 8. The XRPD of Dolasetron mesylate Form VIII_exhibits following peaks:

Position [°2θ] Rel. Int. [%]
7.5963 4.24
9.3846 8.81
12.3236 59.04
13.5267 3.90
14.1731 48.06
15.0400 50.64
16.2205 100.00
18.3240 92.38
18.6858 20.79
19.3579 4.00
20.7258 37.10
21.0127 82.31
22.0929 80.73
22.5425 91.43
23.7057 35.67
24.8243 13.17
25.9718 21.22
26.6736 10.77
27.9853 26.04
29.1333 33.12
25

29.7016 16.86
30.1635 12.14
31.2731 12.07
32.5971 8.36
33.5183 8.64
34.7327 10.71
37.0768 10.79
45.7888 3.36
Polymorphic Form IX of Dolasetron mesylate is obtained from Dolasetron
mesylate by solvent and anti-solvent combination process. The solvent used for
dissolution is selected from lower aliphatic alcohols. The lower alcohol is selected from
methanol, ethanol and n-propanol. The anti-solvent is selected from a group of lower
aliphatic ethers. The lower aliphatic ether is selected from diethyl ether, diisopropyl ether,
and methyl tert. butyl ether. The XRPD of Dolaserron mesylate Form IX is given in
Figure 9. The XRPD of Dolasetron mesylate Form IX exhibits following peaks:

Position [°2 θ] Rel. Int. [%]
8.9186 5.25
9.5043 13.32
9.9342 8.08
11.3309 10.50
12.2006 27.86
13.0074 25.17
13.5809 26.51
14.2218 66.49
14.7381 39.30
15.1831 41.45
16.5427 21.94
16.9310 24.23
19.0277 29.88
19.7369 88.83
20.3022 100.00
21.2529 23.15
22.5030 75.37
23.1298 18.84
24.3308 15.61
26.5618 14.00
27.3363 28.13
28.3123 62.31
30.1981 35.94
32.6226 11.17
33.8362 12.52
26

Amorphous form of Dolasetron mesylate is obtained by lyophilization or vacuum
evaporation or by spray drying. The solution of Dolasetron mesylate in polar protic
solvents is subjected to lyophilization or vacuum evaporation or spray drying to obtain the
amorphous form, The polar protic solvent used for dissolution is lower alcohols or water.
The lower alcohols are selected from methanol, ethanol, and n-propanol.
Another process to obtain amorphous form is melt crystallization, comprising:
melting Dolasetron mesylate at a temperature range of 150-170°C, preferably in the range
of 160-165°C and cooling the melt at a temperature range of 25-45°C, preferably in the
range of 25-30°C. The XRPD of amorphous Form is given in Figure 10.
The crystallization process hitherto described to prepare the novel polymorphs
comprises, dissolving Dolasetron mesylate in the selected solvent either with or without
heating, preferably with heating at or near boiling point of the solvent. The resultant
solution is cooled to -5°C to 30°C for several hours to regenerate the solid. The
precipitated solids are isolated and dried at about ambient to 65°C temperature.
The solvent and anti-solvent combination process described to prepare the novel
polymorphs comprises dissolving Dolasetron mesylate in the selected solvent. The
dissolution is carried out at room temperature or under reflux condition. Anti-solvent is
added to the resulting solution under warm conditions to regenerate Dolasetron mesylate.
The anti-solvent addition is generally carried out at room temperature or at 35°C-55°C.
The precipitated solids are isolated and dried at about ambient to 65°C temperature.
Treatment process described hitherto to prepare Form VIII comprises, suspending
Dolasetron mesylate in the selected solvent, refluxing the suspension for 1 hr, and cooling
the suspension to -5°C to 30° C, preferably to room temperature under stirring for 3 hr.
The solids are isolated and dried at about ambient to 65°C temperature to obtain
crystalline Form VIII.
The melt crystallization technique described to prepare amorphous form comprises
heating of Dolasetron mesylate to form a melt. The heating is generally carried out at
temperature below 175°C. The melt of Dolasetron mesylate is generally formed in the
temperature range of 150°C -175°C, preferably 160°C. The melt is allowed to solidify at
-5°C to 30°C to provide the novel amorphous form.
The vacuum evaporation technique described to prepare amorphous form consists
of evaporation of the solvent from Dolasetron mesylate solution under vacuum.
27

The spray drying technique described to prepare amorphous form Dolasetron mesylate
consist of aspirating the solution of Dolasetron mesylate at the inlet temperature range of
120°C to 180°C, preferably 155°C- 165°C and outlet temperature range of 60°C to 110°C,
preferably 95°C-105°C.
The lyophilisation technique described to prepare amorphous form consists of
freeze drying an aqueous solution of Dolasetron mesylate.
The novel polymorphs of Dolasetron mesylate are characterized by X-ray powder
diffraction. X-ray powder diffraction pattern has been obtained on Xpert'PRO, Panalytical
diffractometer equipped with accelerator detector using Copper Ka (X= 1.5406 A)
radiation with scanning range between 4-50° 26 at a scanning speed of 2°/min.
The present invention is described herein below with examples, which are
illustrative only and should not be construed to limit the scope of the present invention in
any manner,
EXAMPLES
Example 1: Preparation of ethyl-3-cyclopentene-l-carboxylate (5)
A solution of 3-cyclopentene-l-carboxylic acid (500 g, 4.45 mole) in ethanol (500
mL) was stirred at 5-10°C. Then thionyl chloride (257.59 g, 2.16 mole) was added in a
drop wise manner for 1 hr. After complete addition was over, the reaction mixture was
stirred at room temperature for 30 min. The reaction mixture was poured into the water
(1000 mL) and extracted with ethyl acetate (2 x 250 mL). The ethyl acetate layer was
washed with 10% sodium carbonate solution (500 mL), with water (2 x 500 mL) and
concentrated to give ethyl-3-cyclopentene-1-carboxylate (5).
Yield: 558g, 89.42%.
Example 2: Preparation of l-ethoxycarbonyI-3-cycIopenteneoxide (19)
A solution of ethyl-3-cyclopentene-l-carboxylate (5) (1 Kg, 7.13 mole) in
dichloromethane (8 L) was stirred at 5-10°C. Then 70 % meta-chloroperbenzoic acid (2.4
Kg, 9.73 mole) was added in lots for 1 hr at 5-10°C. The reaction mixture was stirred at 5-
10 C for 3 hr. The reaction was monitored using gas chromatography. The reaction
mixture was filtered and cake washed with dichloromethane (2 x j L). The filtrate was
washed with 10 % sodium metabisulphite (5 L), 10 % sodium carbonate (10 L), dried over
sodium sulphate and concentrated to give l-ethoxycarbonyl-3-cyclopenteneoxide (19).
Yield: 1.1 Kg, 98.74%.
Example 3: Preparation of B-ethoxycarbonylglutaraldehyde (8)
28

A suspension of periodic acid (1.5 Kg, 6.58 mole) in ethyl acetate (3 L) was stirred
at 0-10°C under nitrogen atmosphere. Then was added l-ethoxycarbonyl-3-
cyclopenteneoxide (19) (1 Kg, 6.40 mole) in ethyl acetate (3 L) in a drop wise manner at
0-10°C for Ihr. The reaction mixture was stirred at 0-10°C for 4 hr. The reaction mixture
was filtered through celite. The filtrate was washed with water (2 X 750 mL). The ethyl
acetate layer was diluted with water (3 L), From this mixture ethyl acetate was evaporated
at 30-35°C under vacuum and aqueous layer that remained contained 13-
ethoxycarbonylglutaraldehyde (7), This aqueous solution was directly used in the next
step.
Example 4: Preparation of 7-ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-
azabicyclo- [3.3.1] nonan-3-one (8)
A suspension of potassium hydrogen phthalate (2.5 Kg, 12.24 mole) in water (2 L)
was stirred at room temperature. Then acetonedicarboxylic acid (1.15 Kg, 8.23 mole) in
water (1.4 L) and glycine ethyl ester (1.15 Kg, 8.23 mole) in water (1.6 L) were added to
the reaction mixture at 15-20 C. The aqueous solution containing B-ethoxycarbonyl
glutaraldehyde (7) was added in a drop wise manner for 1 hr under nitrogen atmosphere.
The reaction mixture was stirred for 12 hr at room temperature and the pH was adjusted to
8-8.5 by the addition of the potassium carbonate and extracted with ethyl acetate (3 X1000
mL). The ethyl acetate layer was separated, washed with water and concentrated to give 7-
ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1] nonan-3-one (8). Yield:
1.05 Kg, 55.14%.
Example 5: Preparation of 7-ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-
azabicyclo-[3.3.1] nonan-3-ol (9)
To a solution of 7-ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-azabicyclo-
[3.3.1]nonan-3-one (8) (450 g, 1.51 mole) in ethanol (4.5 L) was added,
sodiumborohydride (175 g, 4.62 mole) in a portion wise manner for 30 min at 10-15°C.
The reaction mixture was stirred at room temperature for 2 hr and the pH was adjusted to
7 by the addition of the acetic acid. The solid was filtered and the filtrate was concentrated
to yellow residue. Water (1.2 L) was added to the residue and the reaction mixture was
basified using 10% potassium carbonate solution and extracted with ethyl acetate (3 x 600
mL). The ethyl acetate layer was separated and concentrated to give 7-ethoxycarbonyl-9-
(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1] nonan-3-ol (9). Yield: 365 g, 80.56%.
29

Example 6: Preparation of 3-tertiary-butyI dimethylsilyloxy-7-ethoxycarbonyl-9-
(ethoxycarbonylrnethyl)-9-azabicyclo-[3.3.1)nonan-3-ol(20)
A solution of 7-ethoxycarbonyl-9-(ethoxycarbonylmethyl)-9-azabicyclo-
[3.3.1]nonan-3-ol (9) (351 g, 1.17 mole), imidazole (239 g, 3.51 mole) and t-
butyldimethylsilyl chloride (265 g, 1.7 mole) in N,N-dirnethylformamide (700 mL) was
stirred at 10°C for 30 min. The reaction mixture was stirred at room temperature for 2 hr,
after which it was poured into water (5 L) and extracted with ethyl acetate (3 x 500 ml).
The ethyl acetate layer was separated, washed with water (3 X1000 mL) and
concentrated to give 3-tertiary butyl dimethylsilyloxy 7-ethoxycarbonyl-9-
(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1]nonan-3-ol (20). Yield: 480 g, 99.17%.
'HNMR: 200MHz, CDC13; the chemical shifts expressed are in 5.
0.1 (s, 6H, 2 x CH3); 0.93 (m, 15H, 5 x CH3); 4.1 to 4.26 (m, 4H, 2 x CH2); 1.27 to 3.47
(m, 13H, 5xCH2 + 3xCH).
Example 7: Preparation of endo-hexahydro-8-(t-butyldimethylsilyloxy)-2-
ethoxycarboayl-2,6-rnethano-2H-quinoIizin-3-(4H)-one (21)
A mixture of 3-(t-butyldimethylsilyloxy)-7-ethoxycarbonyl-9-
(ethoxycarbonylmethyl)-9-azabicyclo-[3.3.1]nonan-3-ol (20) (480 g, 1.16 mole) and
potassium t-butoxide (235 g, 2.09 mole) in toluene (4.5 L) was refluxed under nitrogen
atmosphere for 2 hr. Acetic acid (140 mL) was added to the reaction mixture at 10-15°C
followed by water (500 mL). The reaction mixture was extracted with ethyl acetate (3,0
L), the ethyl acetate layer was separated, washed with water and concentrated to obtain
endo-hexahydro-8-(t-butyldimethylsilyloxy)-2-ethoxycarbonyl-2,6-methano-2H-
quinolizin-3-(4H)-one(21). Yield: 270 g, 92.15%.
'HNMR: 200MHz, CDC13; the chemical shifts expressed are in d.
0.08 (s, 6H, 2 x CH3); 0.89 (m, 12H, 4 x CH3); 4.1 to 4,23 (m, 4H, 2 x CH2); 1.23 to 4.2
& 4,81 to 5.3 (m, 12H, 5 x CH2 + 2 x CH).
Example 8: Preparation of endo-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-
3-(4H)-one (11)
To the oily compound, endo-hexahydro-8-(t-butyldimethytsilyloxy)-2-
ethoxycarbonyl-2,6-methano-2H-quinolizin-3-(4H)-one (21) (100 g, 0.39 mole) in water
30

(200 mL) concentrated hydrochloric acid (50 mL) was added. The reaction mixture was
refluxed for 16 hr, cooled to room temperature and basified with potassium carbonate till
pH becomes 8-8.5. This solution was concentrated under reduced pressure to obtain a
residue. This residue was treated with 50% methanol in dichloromethane to precipitate
inorganic material. This inorganic material was separated by filtration and filtrate was
concentrated to give endo-hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one
(11). Yield: 26 g, 36.34%.
Example 9: Preparation of endo-hexahydro-8-hydroxy-2,6-mertiano-2H-quiflo]izin-
3-(4H)-one (11)
To the oily compound, endo-hexahydro-8-(t-butyldimethylsiryloxy)-2-
ethoxycarbonyI-2,6-methano-2H-quinoIizin-3-(4H)-one (21) (100 g, 0.39 mole) in water
(200 mL) was added concentrated hydrochloric acid (50 mL). The reaction mixture was
refluxed for 16 h cooled to room temperature and basified with potassium carbonate till
pH becomes 8-8.5. This solution was extracted with n-butanol. The butanol layer was
separated and concentrated under reduced to give endo-hexahydro-8-hydroxy-2,6-
methano-2H-quinolizin-3-(4H)-one (11). Yield: 25.5 g, 35.64%.
Example 10: Preparation of endo-hexahydro-8-hydroxy-2,6-methano-2H-qurnolizin-
3-(4H)-one(ll)
To the oily compound endo-hexahydro-8-(t-butyldimethylsilyloxy)-2-
ethoxycarbonyl-2,6-methano-2H-quinolizin-3-(4H)-one (21) (100 g, 0.39 mole) in water
(200 mL) was added concentrated hydrochloric acid (50 mL). The reaction mixture was
refluxed for 16 hr and cooled to room temperature and basified with potassium carbonate
till pH becomes 8-8.5. This solution was saturated with sodium chloride and extracted
with isopropanol. The isopropanol layer was separated and concentrated under reduced
pressure to give residue. This residue was treated with'dichloromethane and clear solution
of dichloromethane was filtered and concentrated to provide endo-hexahydro-8-hydroxy-
2,6-methano-2H-quinolizin-3-(4H)-one (11). Yield: 25.5 g, 35.64%.
EXAMPLE 11: Preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-
methano-2H-quinolizin-3(4H)-one (Dolasetron base).
31

A solution of trifluoroacetic anhydride (413.7 g, 1.97 mole) in dichloromethane
(1700 mL) was stirred under nitrogen atmosphere and to this, indole-3-carboxylic acid
(302 g, 1.87 moles) was added in a portion wise manner for 30 min at -5 to 0°C. The
reaction mixture was stirred further 30 min at -5 to 0°C. Then endo-hexahydro-8-
hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one (Step VII) (170 g, 0.939 moles) in
dichloromethane (850 mL) was added in a drop wise manner for 30 min at -5 to 0°C and
was added dimethyl amino pyridine (1.43 g). The reaction mixture was stirred further for
12 h at room temperature. The reaction mixture was filtered and the collected solid washed
with dichloromethane (3 x 170 mL). The solid was stirred in water (2550 ml) and 10%
sodium carbonate (1360 mL) for 30 min. The solid formed was filtered and washed with
water. This solid was stirred with 5 % methanesulphonic acid (850 mL) for 1 h and
filtered to remove excess undissolved indole 3-carboxylic acid. The filtrate was extracted
with ethyl acetate (3 x 340 ml) and the ethyl acetate layer was separated. The aqueous
acidic layer was basified with 10% sodium carbonate (850 mL), solid was separated.
filtered and washed with water. Dried the wet solid (Dolasetron base).
Yield: 127 g, 42%.
Example 12: Preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-
methano-2H-quinoIizin-3(4H)-one (Dolasetron base)
A solution of trifluoroacetic anhydride (121.8 g, 0.57 mole) in dichloromethane
(750 mL) was stirred under nitrogen atmosphere and to this, indole-3-carboxylic acid (88
g, 0.54 mole) was added in a portion wise manner for 30 min at 0 to 5°C. The reaction
mixture was stirred for further 30 min at 0-5°C. Then endo-hexahydro-8-hydroxy-2,6-
methano-2H-quinolizin-3-(4H)-one (11) (50 g, 0.27 mole) in dichloromethane (500 mL)
and dimethyl amino pyridine (0.42 g, 0.0039 mole) were added in a drop wise manner for
30 min at 0-5 C. The reaction mixture was stirred further for 12 h at room temperature.
The reaction mixture was filtered and the collected solid washed with dichloromethane
(100 mL). The solid was stirred in ethyl acetate (550 mL) and 10% sodium carbonate (500
mL) was further added. The ethyl acetate layer was separated, washed with water and
concentrated to obtain crude Dolasetron base (60 g). The crude base was recrystallized
from ethyl acetate-hexane to give pure Dolasetron base.
Yield: 50 g, 50.63%.
32

Example 13: Preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-
methano-2H-quinolizin-3(4H)-one mesylate
Dolasetron base (50 g, 0.15 mole) was dissolved in acetone (1000 mL) and
methane sulphonic acid was added (10.70 mL) drop wise over a period of 30 min at 20 C.
The reaction mixture was stirred further for 2 hr. The solid formed was filtered, washed
with cold acetone (50 mL) and dried. Yield (crude) 59 g, 90.77%.
Example 14: Purification of endo-hexahydro-8-{3-indolylcarbonyloxy)-2,6-
methano-2H-quinolizin-3(4H)-one mesylate, Dolasetron mesylate.
Dolasetron mesylate crude (59 g) was dissolved in hot 5% aqueous isopropanol
(500 mL) treated with charcoal and filtered hot. Diethyl ether (50 mL) was added to the
filtrate, the solid formed was filtered and dried. Yield 50 g, 82.71%. Purity: 99.9%
(HPLC).
Example 15: Preparation of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-
metbano-2H-qiiinolizin-3(4H)-one mesylate hydrate.
To Dolasetron base (119 g, 0.368 moles) (Step VIII) was dissolved in acetone
(2023 mL) and treated with activated charcoal (12 g). Filtered the mixture through hyflow
and the clear solution was treated with water (24 ml) and methane sulphonic acid (38.96 g,
0.405 moles) at 25-30°C. The reaction mass was stirred further for 2 h at 0-5°C. The solid
formed was filtered, washed with acetone (3 x 120 mL) and dried. Yield (crude) HO g,
87%.
Example 16: Purification of endo-hexahydro-8-(3-indolylcarbonyloxy)-2,6-
methano-2H-quinolizin-3(4H)-one mesylate, Dolasetron mesylate hydrate.
The Dolasetron mesylate (140 g) (Step IX) was taken in water (900 ml) and
extracted with ethyl acetate (3x280 ml). The aqueous layer was separated, basified with
10% sodium carbonate (320 mL). The solid obtained was filtered, washed with water and
dried. This solid was dissolved in acetone (2 xlOO mL) and treated with activated charcoal
(12 g). Filtered the mixture through hyflow and clear solution was treated with water (20
mL) and methane sulphonic acid (32.72 g, 0.341 moles) at:25-30°C. The reaction mass
33

was stirred further for 2 h at 0-5°C. The solid formed was filtered, washed with acetone (3
xlOO mL) and dried. Yield 130 g, 93%. Purity: 99.9% (HPLC).
PREPARATION OF POLYMORPHIC FORMS OF DOLASETRON MESYLATE
Preparation of Dolasetron mesylate Form I
Example 17
0.5g of Dolasetron mesylate was dissolved in 30 mL of IPA at reflux temperature.
The hot solution was allowed to cool to room temperature. The solution was stirred at the
same temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get
Dolasetron mesylate Form I. (Kf = 4.85%)
Example 18
0.5g of Dolasetron mesylate was dissolved in 20 mL of acetonitrile at reflux
temperature. The hot solution was allowed to cool to room temperature. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I. (Kf = 4.56%)
Example 19
0.5g of Dolasetron mesylate was dissolved in 20 mL of acetone at reflux
temperature. The hot solution was allowed to cool to room temperature. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I. (Kf = 5.32%)
Example 20
0.5g of Dolasetron mesylate was dissolved in 50 mL of ethyl acetate at reflux
temperature. The hot solution was allowed to cool to room temperature. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I. (Kf = 4.96%)
Example 21
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMF at room temperature.
To this clear solution 10 mL of THF was added. The solution was stirred at the same
34

temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form I. (Kf = 4.81%)
Example 22
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMF at room temperature.
To this clear solution 10 mL of toluene was added. The solution was stirred at the same
. temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form I. (Kf = 5.28%)
Example 23
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMF at room temperature.
To this clear solution 10 mL of IP A was added. The solution was stirred at the same
temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form I. (Kf = 4.75%)
Example 24
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMSO at room temperature.
To this clear solution 10 mL of THF was added. The solution was stirred at the same
temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form I, (Kf = 5.32%)
Example 25
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMSO at room temperature.
To this clear solution 10 mL of toluene was added. The solution was stirred at the same
temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolaserron
mesylate Form I. (Kf = 5.68%)
Example 26
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMSO at room temperature.
To this clear solution 10 mL of IP A was added. The solution was stirred at the same
temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form I. (Kf = 4.52%)
Example 27
35

0.5g of Dolasetron mesylate was dissolved in 2 mL of N,N-dimethyl acetamide at
room temperature. To this clear solution 10 mL of THF was added. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I, (Kf = 4.95%)
Example 28
0.5g of Dolasetron mesylate was dissolved in 2 mL of N,N-dimethyl acetamide at
room temperature. To this clear solution 10 mL of toluene was added. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I. (Kf = 5.12%)
Example 29
0.5g of Dolasetron mesylate was dissolved in 2 mL of N, N-dimethyl acetamide at
room temperature. To this clear solution 10 mL of IPA was added. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form I. (Kf = 4.82%)
Preparation of Dolasetron mesylate Form H
Example 30
0.5g of Dolasetron mesylate was dissolved in 5 mL of methanol at reflux
temperature. The hot solution was allowed to cool to 5°C. The solution was stirred at the
same temperature for 12 hr. The solid obtained was filtered and dried at 65°C to get
Dolasetron mesylate Form II. (Kf = 2.60%)
Preparation of Dolasetron mesylate Form III
Example 31
0.5g of Dolasetron mesylate was dissolved in 10 mL of ethanol at reflux
temperature. The hot solution was allowed to cool to 5°C for 2 hr and the solution was
stirred at the same temperature for 12 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form HI. (Kf = 5.48%)
Example 32
0.5g of Dolasetron mesylate was dissolved in 20 mL of ethanol at reflux
temperature. The hot solution was allowed to cool to 45°C and to this was added 50 mL of
n-hexane. The resultant slurry was stirred for 2 hr and the solution was stirred at the same
36

temperature for 3 hr. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form III. (Kf = 4.81 %).
Preparation of Dolasetron mesylate Form IV
Example 33
0.5g of Dolasetron mesylate was dissolved in 5 mL of n-propanol at reflux
temperature. The hot solution was allowed to cool to 5°C for 2 hr and the solution was
stirred at the same temperature for 12 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form IV. (Kf = 5.66%).
Preparation of Dolasetron mesylate Form V
Example 34
0.5g of Dolasetron mesylate was dissolved in 75 mL of chloroform at reflux
temperature. The hot solution was maintained at the same temperature for 30 min. The hot
solution was allowed to cool to room temperature and was stirred for 3 hr at the same
temperature. The solid obtained was filtered and dried at 65°C to get Dolasetron mesylate
FormV. (Kr=5.83%)
Example 35
0.5g of Dolasetron mesylate was dissolved in 75 mL of methylene dichloride at
reflux temperature. The hot solution was maintained at the same temperature for 30 min.
The hot solution was allowed to cool to room temperature and was stirred for 3 hr at the
same temperature. The solid obtained was filtered and dried at 65°C to get Dolasetron
mesylate Form V. (Kf = 7.69%)
Preparation of Dolasetron mesylate Form VI
Example 36
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMF at room temperature.
To this solution 20 mL of 1,4-dioxane was added at room temperature. The solution was
stirred at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form VI. (Kf = 4.69%)
Example 37
0.5g of Dolasetron mesylate was dissolved in 2 mL of DMSO at room temperature.
To this solution 10 mL of 1,4-dioxane was added at room temperature. The solution was
37

suncd at the same temperature for 3 hr. The solid obtained was filtered and dried at 65°C
to get Dolasetron mesylate Form VI. (Kf = 4.46%)
Preparation of Dolasetron mesylate Form VII
Example 38
0,5g of Dolasetron mesylate was dissolved in 2 rnL of N,N-dimethyl acetamide at
room temperature. To this solution 20 mL of 1,4-dioxane was added at room temperature.
The solution was stirred at the same temperature for 3 hr. The solid obtained was filtered
and dried at 65°C to get Dolasetron mesylate Form VII. (Kr= 4.80%)
Preparation of Dolasetron mesylate Form VIII
Example 39
0.5g of Dolasetron mesylate was suspended in 20 mL of ethyl methyl ketone and
the solution was heated to reflux for 1 hr. The solution was cooled to room temperature.
The solution was stirred at the same temperature for 3 hr. The solid obtained was filtered
and dried at 65°C to get Dolasetron mesylate Form VIII. (Kf = 8.01%)
Preparation of Dolasetron mesylate Form IX
Example 40
0.5g of Dolasetron mesylate was suspended in 20 mL of ethanol and the solution
was heated to reflux for 1 hr. The solution was cooled to 45°C temperature. To this hot
solution, 50 mL of diisopropyl ether was added and the solution was stirred at 30°C for 3
hr. The solid obtained was filtered and dried at 65 °C to get Dolasetron mesylate Form IX.
(Kf=5.04%).
Preparation of amorphous form of Dolasetron mesylate
Example 41
0.5g of Dolasetron mesylate was suspended in 20 mL of methanol. The solution
was warmed to 60°C to get a clear solution. The hot solution was distilled under vacuum
at 55-60°C under pressure. The solid obtained by this method was maintained at same
temperature and pressure to remove any traces of solvent. The solid obtained was
amorphous form of Dolasetron mesylate. (Kf = 4.81%)
Example 42
38

0.5g of Dolasetron mesylate was suspended in 10 mL of water. The solution was
warmed to 60°C to get a clear solution. The hot solution was distilled under vacuum at 55-
60°C under pressure. The solid obtained by this method was maintained at same
temperature and pressure to remove any traces'of solvent. The solid obtained was
amorphous form of Dolasetron mesylate. (Kf = 4.96%)
Example 43
0.5g of Dolasetron mesylate was suspended in clean and dry 100 mL round bottom
flask and the flask was heated to 160°C to melt the solid in to liquid. The melt solid was
heated to 120° for 3 hr. The solid obtained was amorphous form of Dolasetron mesylate.
(Kf = 4.92%)
Example 44
A 50 mL aqueous solution of Dolasetron mesylate was frozen using dry ice bath
and dried by lyophilization for 24 hr.
Example 45
A 50mL aqueous solution of Dolasetron mesylate at a concentration of 20%
weight/volume and at a temperature of 30°C was spray dried by a spray gun (PSD 00
Pilot, Hemraj, India at pressure 500 to 600 psi and flow rate of 2 L/hr) at an inlet
temperature of 165°C and outlet temperature of 105°C of the spray gun.
Example 46
The procedure of Example 45 was carried out at inlet temperature of 155°C and
outlet temperature of 95°C of the spray gun.
39

I/We claim:
1. A process for producing polymorphic Form I of Dolasetron mesylate comprising:
dissolving Dolasetron mesylate in a solubilizing solvent at a temperature in the range of
30°C to 80°C, cooling at a temperature in the range of 0°C to 30°C, isolating and drying
the product at a temperature in the range of 30°C to 90°C.
2. The process as claimed in claim 1 , wherein the solubilizing solvent is selected
from isopropanol, acetonitrile, ethyl acetate, acetone or mixture thereof.
3. A process for producing polymorphic Form I of Dolasetron mesylate comprising:
dissolving Dolasetron mesylate in a solubilizing solvent, adding an anti-solvent, stirring
the suspension with or without cooling for about one hour to about eight hours, isolating
and drying the product at a temperature range of 30°C to 90°C.
4. The process as claimed in claim 3, wherein the solubilizing solvent is selected
from polar aprotic solvents.
5. The process as claimed in claim 4, wherein the polar aprotic solvent is selected
from dimethyl formamide, dimethyl sulfoxide, N, N-dimethyl acetamide or mixture
thereof,
6. The process as claimed in claim 3, wherein the anti-solvent is selected from a
group of tetrahydrofuran, toluene, isopropanol or mixture thereof.
7. A crystalline polymorphic Form II of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methane sulfonate, Dolasetron mesylate
characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 20: 8.5677, 14.3549,
15.3566, 16.1189, 17.4727, 17.9848, 18.2788, 19.9142, 20.3327, 20.7258,
21.4927, 24.4864, 27.5344 and 28.2995 ± 0.2 degrees.
8. A process for producing polymorphic Form II of Dolasetron mesylate of claim 7
comprising: dissolving Dolasetron mesylate in methanol at a temperature in the range of
30°C to 80°C, cooling to a temperature in the range of 2°C to 7°C, isolating a residue and
drying the residue at a temperature in the range of 30°C to 90°C,
40

9. A crystalline polymorphic Form HI of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron mesylate
characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 20: 6.9327, 12.6509,
13.7701, 16.6416, 17.5613, 18.1133, 19.4364, 19.6530, 20.5969, 21.2122,
22.1215, 22.3203, 22.9997, 27.9040 and 29.5991 ± 0.2 degrees.
10. A process for producing polymorphic Form III of Dolasetron mesylate of claim 9
comprising: dissolving Dolasetron mesylate in ethanol at a temperature in the range of
30°C to 80°C, cooling to a temperature in the range of -5°C to 30°C, isolating a product
and drying the product at a temperature in the range of 30°C to 90°C.
11. A process for producing polymorphic Form III of Dolasetron mesylate of claim 9
comprising: dissolving Dolasetron mesylate in a solubilizing solvent at an elevated
temperature in the range of 60°C to 80°C, adding an anti-solvent at a temperature in the
range of 30°C to 55°C, isolating a product and drying the product at a temperature in the
range of 30°C to 90°C.
12. The process as claimed in claim 11, wherein the solubilizing solvent is selected
from methanol, ethanol, n-propanol and isopropanol.
13. The process as claimed in claim 11, wherein the solubilizing solvent is ethanol.
14. The process as claimed in claim 11, wherein the anti-solvent is an aliphatic
hydrocarbon.
15. The process as claimed in claim 14, wherein the aliphatic hydrocarbon is selected from
n-pentane, n-hexane and n-heptane.
16. The process as claimed in claim 14, wherein the aliphatic hydrocarbon is n-hexane.
17. A crystalline polymorphic Form IV of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron mesylate
characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 26:8.9231,
12.1275, 12.5348, 12.7100, 14.0712, 14.8069, 16.6676, 17.3884, 18.9666,
19.2953, 19.9217,20.8115,22.0471 and 22.4082 ± 0.2 degrees.
41

18. A process for producing polymorphic Form IV of Dolasetron mesylate of claim 17
comprising: dissolving Dolasetron mesylate in n-propanol at a temperature in the range of
30°C to 100°C, cooling to a temperature in the range of-5°C to 30°C, isolating a product
and drying the product at a temperature in the range of 30°C to 90°C.
19. A crystalline polymorphic Form V of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron mesylate
characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 26: 7.0234, 9.4499,
11.2346, 12.3990, 13.5899, 14.2116, 14.9901, 16.4007, 18.7313, 20.3109,
20.7126, 21.2339, 22.2956, 23.8661,24.2519, 24.8389, 28.8706 ± 0.2 degrees.
20. A process for producing polymorphic Form V of Dolasetron mesylate of claim 19
comprising: dissolving Dolasetron mesylate in a solubilizing solvent at a temperature at a
temperature in the range of 30°C to 80°C, cooling to a temperature in the range of-5°C to
30°C, isolating a product and drying the product at a temperature in the range of 30°C to
90°C.
21. The process as claimed in claim 20, wherein the solubilizing solvent is a
chlorinated hydrocarbon.
22. The process as claimed in claim 20, wherein the chlorinated hydrocarbon is either
chloroform or methylene dichloride.
23. A crystalline polymorphic Form VI of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron mesylate
characterized by (he X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 26: 7.4433, 9.5049,
9.9496, 10.5039, 12.6288, 13.3801, 13.7613, 16.6316, 17.8499, 19.0352, 19.3432,
20.4909 and 21.8514 ± 0.2 degrees.
24. A process for producing polymorphic Form VI of Dolasetron mesylate of claim 23
comprising: dissolving Dolasetron mesylate in a solubilizing solvent at a temperature in
the range of 20°C to 35°C, adding an anti-solvent at a temperature range of 20°C to 45°C,
isolating and drying the product at a temperature in the range of 30°C to 90°C.
42

25. The process as claimed in claim 24, wherein the solubilizing solvent is a polar
aprotic solvent.
26. The process as claimed in claim 25, wherein the polar aprotic solvent is either
dimethyl formamide or dimethyl sulfoxide.
27. The process as claimed in claim 24, wherein the anti-solvent is 1,4-dioxane.
28. A crystalline polymorphic Form VII of endo-hexahydro-8-(3-
indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron
mesylate, characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 20: 9.4384, 12.5519,
13.3180, 16.5925, 17.2066, 17.7820, 18.9901/19.2914, 20.5000, 20.9102,
21.2835, 21.7867, 22.0779, 22.7162, 27.1538 and 29.0636 ± 0.2 degrees.
29. A process for producing polymorphic Form VII of Dolasetron mesylate of
claim 2S comprising: dissolving Ddasetron mesylate in N,N-dimerthyl acetamide at a
temperature in the range of 20°C to 35°C, adding an anti-solvent at a temperature in the
range of 20°C to 45°C, isolating and drying the product at a temperature in the range of
30°C to 90°C.
30. The process as claimed in claim 29, wherein the anti-solvent is 1, 4-dioxane.
31. A crystalline polymorphic Form VIII of endo-hexahydro-8-(3-
indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron
mesylate, characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 29: 9,3846, 12.3236,
14.1731, 15.0400, 16.2205, 18.3240, 20.7258, 21.0127, 22.0929, 22.5425 and
23.7057 ±0.2 degrees.
32. A process for producing polymorphic Form VIII of Dolasetron mesylate of
claim 31 comprising: suspending Dolasetron mesylate in ethyl methyl ketone, heating at
an elevated temperature in the range of 40°C to 80°C for one hour, stirring the solution
with cooling to a temperature in the range of-5°C to 30oC, isolating a product and drying
the product at a temperature in the range of 30°C to 90°C.
43

33. A crystalline polymorphic Form IX of endo-hexahydro-8-(3-indolylcarbonyloxy)-
2,6-methano-2H-quinolizin-3(4H)-one methanesulfonate, Dolasetron mesylate,
characterized by the X-ray powder diffraction pattern as given below:
Peaks in the powder X-ray diffraction pattern are at about 26: 8.9186, 9.5043,
9,9342, 12.2006, 13,0074, 13.5809, 14.2218, 15.1831, 19,0277, 19.7369,20.3022,
21.2529 and 22.5030 + 0.2 degrees.
34. A process for producing polymorphic Form IX of Dolasetron mesylate of claim 33
comprising: dissolving Dolasetron mesylate in a solubilizing solvent at a temperature in
the range of 60°C to 80°C, adding an anti-solvent at a temperature in the range of 30°C to
55°C, isolating and drying the product at a temperature in the range of 30°C to 90°C.
35. The process as claimed in claim 34, wherein the solubilizing solvent is selected
from a group consisting of methanol, ethanol and n-propanol.
36. The process as claimed in claim 34, wherein the solubilizing solvent is ethanol.
37. The process as claimed in claim 34, wherein the anti-solvent is aliphatic ether.
38. The process as claimed in claim 37, wherein the aliphatic ether is selected from a
group consisting of diethyl ether, diisopropyl ether and methyl tert-butyl ether.
39. The process as claimed in claim 37, wherein the aliphatic ether is diisopropyl
ether.
40. An amorphous form of endo-hexahydro-8-(3-indolylcarbonyloxy)-2, 6-methano-
2H-quinolizin-3 (4H)-one methanesulfonate (Dolasetron mesylate).
41. A process for preparation of amorphous form of Dolasetron mesylate of claim 40
comprising: dissolving Dolasetron mesylate in polar protic solvents and vacuum
evaporating the solution.
42. The process claimed in claim 41, wherein the polar protic solvent is selected from
methanol, ethanol, n-propanol and water.
43. A process for preparation of amorphous form of Dolasetron mesylate of claim 40
comprising: dissolving Dolasetron mesylate in polar protic solvents and lyophilizing the
solution.
44. The process as claimed in claim 43, wherein the polar protic solvent is selected
from methanol, ethanol, n-propanol and water.
44

45. The process as claimed in claim 43, wherein the polar protic solvent is water.
46. A process for preparation of amorphous form of Dolasetron mesylate of claim 40,
comprising: dissolving Dolasetron mesylate in polar protic solvents and spray drying the
solution.
47. The process as claimed in claim 46, wherein the polar protic solvent is selected
from methanol, ethanol, n-propanol and water.
48. The process as claimed in claim 46, wherein the solution is spray dried at an inlet
temperature in the range of 120°C to 180°C.
49. The process as claimed in claim 46, wherein the solution is spray dried at an inlet
temperature in the range.of 155° C to 165°C.
50. The process as claimed in claim 46, wherein the solution is spray dried at an outlet
temperature in the range of 60°C to 110°C.
51. The process as claimed in claim 46, wherein the solution is spray dried at an outlet
temperature in the range of 95°C to 105°C.
52. A process for preparation of amorphous form of Dolasetron mesylate of claim 40
comprising: melting Dolasetron mesylate at a temperature in the range of 150°C to 170°C
and cooling the melt at a temperature in the range of 25°C to 45°C.
53. A process for preparation of amorphous form of Dolasetron mesylate of claim 40
comprising: dissolving Dolasetron mesylate in water and lyophilizing the solution.


DATED THIS 22™ DAY OF DECEMBER 2006
To
The Controller of Patents,
Patent Office at Mumbai
45